Research Context Only
All Figures Describe Research Protocols
BPC-157 is not approved for human use by the FDA or any other major regulatory agency as of 2025. Every dose figure on this page describes what was studied in preclinical animal models or reported in small human pilot studies — not what is recommended, prescribed, or appropriate for human administration. The framing throughout is ‘studied at X µg/kg in species Y via route Z.’ Nothing here constitutes medical advice, clinical guidance, or a prescription.
With that framing established, the preclinical dosage literature for BPC-157 is unusually wide in its range. The compound has been studied at doses spanning twelve orders of magnitude — from 10 picograms per kilogram to 20 milligrams per kilogram — across six routes of administration in rodents, dogs, and three small human cohorts.
Preclinical Dose Range and Routes Studied
The most commonly used preclinical dose in rodent models is 10 micrograms per kilogram (10 µg/kg) by intraperitoneal injection. This dose appears across gastric protection, liver protection, tendon healing, anastomosis healing, NSAID counteraction, and ischemia-reperfusion protection studies. At this dose, researchers have consistently documented protective effects without adverse findings.[1][8][12]
A lower dose of 10 nanograms per kilogram (10 ng/kg) — one thousandth of the 10 µg/kg dose — has been studied extensively and found equipotent to the higher dose in multiple models. Achilles tendon-to-bone healing, intestinal anastomosis promotion, liver protection, and NSAID-toxicity counteraction have all been documented at 10 ng/kg as well as at 10 µg/kg.[11][18] This dose-equivalence across a thousandfold range is a feature of the published literature that authors have noted as unusual but consistent.
An ultra-low dose of 10 picograms per kilogram (10 pg/kg) was studied in the Achilles detachment model, producing measurable improvements in Achilles Functional Index and biomechanical parameters.[11]
| Dose | Route | Species | Models Studied |
|---|---|---|---|
10 pg/kg |
Intraperitoneal | Rat | Achilles tendon-to-bone healing |
10 ng/kg |
IP, oral, IG | Rat | Tendon, anastomosis, liver, NSAID counteraction |
10 µg/kg |
IP, oral, topical | Rat, pig | GI, liver, kidney, tendon, ischemia-reperfusion, NSAID |
0.16 µg/mL |
Drinking water | Rat (~12 mL/day) | GI protection, anastomosis, liver protection |
1 µg/g cream |
Topical | Rat, pig | Wound healing |
2–10 mg/kg |
Intramuscular | Dog (beagle) | 28-day repeated-dose safety / NOAEL |
20 mg/kg |
Intramuscular | Rat | Single-dose tolerance (safety ceiling) |
10–20 mg |
Intravenous infusion | Human (n=2) | IV safety pilot (Lee & Burgess, 2025) |
For oral administration, the primary research model uses drinking water supplemented to a concentration of 0.16 µg/mL, delivering approximately 12 mL per rat per day. Oral-route effects have been documented for gastrointestinal protection, liver protection, NSAID counteraction, and anastomosis healing — consistent with the peptide’s unusual gastric-acid stability.[1][12]
Pharmacokinetics: Half-Life, Bioavailability, and Clearance
The most comprehensive published pharmacokinetic dataset for BPC-157 is He et al. (2022) in Frontiers in Pharmacology, which characterized absorption, distribution, metabolism, and excretion across three escalating intramuscular doses in both Sprague-Dawley rats and beagle dogs, plus a single intravenous dose in each species.[13]
The elimination half-life was under 30 minutes in both species following intramuscular administration.[13] In rats, the time to maximum plasma concentration (Tmax) after intramuscular dosing was approximately 3 minutes. In beagle dogs, Tmax was 6 to 9 minutes post-intramuscular injection. Intramuscular bioavailability was 14 to 19% in rats and 45 to 51% in dogs.[13]
Pharmacokinetics were linear across all doses studied — no saturation kinetics, no dose-dependent accumulation.[13] Primary tissue distribution was to kidney, liver, stomach, spleen, and thymus. Brain accumulation was minimal. Excretion occurred via urine and bile.
Metabolism: BPC-157 breaks down primarily into proline and the other constituent amino acids of its 15-amino-acid sequence, which re-enter normal amino acid metabolic pathways.[13] This pathway produces no documented toxic metabolites and is mechanistically consistent with the compound’s endogenous origin from human gastric juice protein.
Elimination half-life <30 minutes in both rats and beagle dogs (IM); Tmax 3 minutes (rat) and 6–9 minutes (dog); bioavailability 14–19% (rat) and 45–51% (dog) IM; linear kinetics; primary metabolism to proline and standard amino acids; no accumulation.[13]
Human Pilot Dosing: What Was Administered
The three published human pilot datasets represent three different routes and dose presentations.
The Lee and Burgess (2025) intravenous infusion study administered 10 mg BPC-157 by one-hour IV infusion on day one and 20 mg on day two, in two healthy adult volunteers.[6] This is the highest absolute dose administered to humans in any published study. No adverse events were documented at either dose, and comprehensive laboratory monitoring showed no clinically meaningful changes.
The Lee and Padgett (2021) intra-articular knee study administered BPC-157 by direct intra-articular injection in 17 patients with chronic knee pain.[14] The specific dose per injection is not reported in the published abstract; the study was conducted under a clinic protocol. No adverse events were documented.
The intravesicular instillation study for interstitial cystitis administered BPC-157 directly into the bladder via catheter.[21] Dose details are protocol-specific. No adverse effects were reported.
Pilot Data, Not Clinical-Grade Evidence
These are pilot datasets. They establish that BPC-157 has been administered to humans by intravenous, intra-articular, and intravesicular routes without documented adverse events in any published report. They do not constitute clinical-grade safety data and they do not support extrapolation to broader human use. The absence of completed randomized controlled trials is the critical gap in the human evidence base.